PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
-
Over 600 Medical Professionals from 25
Countries Participate
-
Launch of 'IRC' Committee for Rejuran Global
Research Team
Seongnam, South Korea
– PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it
successfully held the 5th PharmaResearch Global Symposium (PGS) at
the Lakai Sandpine Resort on October 28-29, 2024. This year’s event attracted
approximately 600 aesthetic and medical professionals from 25 countries across
Asia, the Americas, Europe, and the Middle East.
The
symposium prominently featured key aesthetic products, particularly Rejuran,
which utilizes PharmaResearch’s proprietary DOT™ (DNA Optimizing Technology)
patented technology.
On
the first day, attendees visited the Inland Water Life Resources Center to
learn about domestic salmon from the Eastern coast, a primary raw material for
PDRN and PN. They also toured the PharmaResearch and PharmaResearch Bio
facilities in Gangneung, where they observed the advanced processes involved in
product manufacturing.
A
participant commented, “It was impressive to see the entire process from
Rejuran’s raw materials to product manufacturing and packaging firsthand. This
experience truly showcased PharmaResearch’s high technological capability and
quality control,” adding, “I now understand why Rejuran is recognized
globally.”
On
the second day, with Dr. Michael J. Kim, Dr. Nark Kyoung Rho, and Dr. Steven
Liew chairing, medical professionals from the United States, Indonesia,
Australia, China, Japan, Ukraine, Malaysia, Kazakhstan, Thailand, and Singapore
shared the latest insights on DOT™PN
and Rejuran through lectures.
Additionally,
the Rejuran Global Research Team ‘International Research Committee (IRC)’ was
officially launched on this day. The IRC, composed of domestic and
international medical professionals, plans to conduct global research based on
Rejuran and DOT™PN.
Dr.
Atchima Suwanchinda, a member of the IRC, stated, “Rejuran has proven
consistent efficacy and safety across various skin types,” adding, “We will
enhance the value of Rejuran through diverse clinical studies and contribute to
establishing it as a trusted medical device for medical professionals in each
country.”
A PharmaResearch official stated, “It is significant that medical professionals from around the world could engage in in-depth discussions on the clinical efficacy and safety of Rejuran through this symposium. Especially with the launch of the IRC, we will activate global research and strive to make Rejuran a globally trusted brand by providing effective solutions tailored to various skin types and conditions.”